Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is -1.87% lower on its value in year-to-date trading and has touched a low of $12.99 and a high of $25.86 in the current 52-week trading range. The RYTM stock was last observed hovering at around $21.96 in the last trading session, with the day’s gains setting it 0.57% off its average median price target of $31.00 for the next 12 months. It is also 47.6% off the consensus price target high of $43.00 offered by 8 analysts, but current levels are -25.17% lower than the price target low of $18.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $22.53, the stock is 0.42% and 7.80% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.21 million and changing 2.60% at the moment leaves the stock 12.69% off its SMA200. RYTM registered 6.68% gain for a year compared to 6-month gain of 9.64%. The firm has a 50-day simple moving average (SMA 50) of $21.62 and a 200-day simple moving average (SMA200) of $18.97.
The stock witnessed a 5.43% loss in the last 1 month and extending the period to 3 months gives it a 21.98%, and is 7.23% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.90% over the week and 5.43% over the month.
Distance from 52-week low is 73.44% and -12.88% from its 52-week high.
Rhythm Pharmaceuticals Inc. (RYTM) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Rhythm Pharmaceuticals Inc. (RYTM) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 7 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Rhythm Pharmaceuticals Inc. is expected to release its quarterly report on 08/05/2020 and quarterly earnings per share for the current quarter are estimated at -$0.83.The EPS is expected to shrink by -61.70% this year.
Rhythm Pharmaceuticals Inc. (RYTM) Top Institutional Holders
149 institutions hold shares in Rhythm Pharmaceuticals Inc. (RYTM), with 2.97M shares held by insiders accounting for 6.73% while institutional investors hold 108.35% of the company’s shares. The shares outstanding are 44.05M, and float is at 40.92M with Short Float at 4.29%. Institutions hold 101.05% of the Float.
The top institutional shareholder in the company is RA Capital Management, L.P. with over 5.42 million shares valued at $82.53 million. The investor’s holdings represent 12.30% of the RYTM Shares outstanding. As of Mar 30, 2020, the second largest holder is NEA Management Company, LLC with 4.91 million shares valued at $74.77 million to account for 11.14% of the shares outstanding. The other top investors are Janus Henderson Group PLC which holds 4.32 million shares representing 9.80% and valued at over $65.74 million, while Primecap Management Company holds 8.03% of the shares totaling 3.54 million with a market value of $53.92 million.
Rhythm Pharmaceuticals Inc. (RYTM) Insider Activity
A total of 39 insider transactions have happened at Rhythm Pharmaceuticals Inc. (RYTM) in the last six months, with sales accounting for 34 and purchases happening 5 times. The most recent transaction is an insider sale by RA CAPITAL MANAGEMENT, L.P., the company’s 10% Owner. SEC filings show that RA CAPITAL MANAGEMENT, L.P. sold 44,153 shares of the company’s common stock on Jul 02 at a price of $22.04 per share for a total of $0.97 million. Following the sale, the insider now owns 5.14 million shares.
Rhythm Pharmaceuticals Inc. disclosed in a document filed with the SEC on Jul 01 that RA CAPITAL MANAGEMENT, L.P. (10% Owner) sold a total of 25,527 shares of the company’s common stock. The trade occurred on Jul 01 and was made at $21.87 per share for $0.56 million. Following the transaction, the insider now directly holds 5.18 million shares of the RYTM stock.
Still, SEC filings show that on Jun 30, RA CAPITAL MANAGEMENT, L.P. (10% Owner) disposed off 61,901 shares at an average price of $22.15 for $1.37 million. The insider now directly holds 5,210,088 shares of Rhythm Pharmaceuticals Inc. (RYTM).
Rhythm Pharmaceuticals Inc. (RYTM): Who are the competitors?
The company’s main competitors (and peers) include PDL BioPharma Inc. (PDLI) that is trading 12.96% up over the past 12 months. Short interest in the company’s stock has risen 10.8% from the last report on May 28, 2020 to stand at a total of 1.57 million short shares sold with a short interest ratio of 7.09.